Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Cervical Heterogenity Imaging Study
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cervical Cancer, Cervical Cancer, Cancer, Women's Studies |
| Therapuetic Areas: | Oncology, Reproductive |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 4/21/2016 |
| Start Date: | August 2008 |
| End Date: | August 2016 |
Assessment of Changes in Pattern and Magnitude of Tumor FDG Uptake During Chemoradiation as a Predictor of Response to Concurrent Radiation Therapy and Chemotherapy in Patients With Cervical Cancer
Rationale: Diagnostic procedures, such as positron emission tomography (PET) using
fluorodeoxyglucose (FDG), may help determine response to standard cancer therapy in patients
with cervical cancer
The purpose of this study is to evaluate the change in cervical tumor heterogenity as
measured by FDG-PET/CT imaging.
fluorodeoxyglucose (FDG), may help determine response to standard cancer therapy in patients
with cervical cancer
The purpose of this study is to evaluate the change in cervical tumor heterogenity as
measured by FDG-PET/CT imaging.
Inclusion Criteria:
1. Biopsy-proven cervical cancer. (FIGO stage-Ib2-IVa)
2. Age ≥ 18
3. Able to receive chemoradiation therapy with Cisplatin.
4. Non-pregnant status in women of childbearing potential.
5. No other active cancer at the time of diagnosis of cervical cancer Patients cannot
have received treatment for any malignancy, with the exception of non-melanoma skin
cancer, in the past 5 years.
6. Patients with distant metastatic disease are eligible provided the estimated survival
of the patient is at least 1 year.
7. Scheduled to undergo or have already undergone FDG-PET/CT imaging for clinical
staging of cervical cancer at Barnes-Jewish Hospital Clinical PET Facility on a
Biograph 40 PET/CT scanner
8. Able to give informed consent
Exclusion Criteria:
1. Age < 18
2. Patients with a known active malignancy other than cervical carcinoma.
3. Pregnant and breastfeeding patients.
4. Subjects whose tumors are not FDG avid on baseline standard of care FDG-PET/CT
imaging
We found this trial at
1
site
Click here to add this to my saved trials
